United States Biotechnology & Medical Research

Fate Therapeutics Inc (FATE)

Track

Over the past 90 days, Fate Therapeutics Inc. has seen 8 insider transactions, all of which were sales totaling approximately $612,144. Key executives, including President and CEO Bahram Valamehr, have consistently sold shares. These transactions occurred following the company's May 2026 results financiers, amid an 8.8% stock price increase over the last quarter.
Ticker: FATE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Fate Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 4 Aug 2026
Value US$1,812,915.89 | Price 495.33 | Shares 49,672 (-16.6%)
Proposed sale 4 Aug 2026
Value US$4,477,461.89 | Price 348.59 | Shares 41,717
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-05 2026-08-04 S Sale
4.0
TAHL CINDY

See Remarks

Officer
49,672 -16.6%
495.33
US$1,812,916 		49,672 -16.6% 495.33 US$1,812,916
2026-08-05 2026-08-04 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
73,259 +25.3%
213.36
US$3,512,886 		73,259 +25.3% 213.36 US$3,512,886
2026-08-04 2026-08-04 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
41,717
348.59
US$4,477,462 		41,717 348.59 US$4,477,462
2026-08-04 2026-08-04 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
1,000
2.46
US$100,000 		1,000 2.46 US$100,000
2026-05-21 2026-05-20 S Sale
4.0
TAHL CINDY

See Remarks

Officer
25,590 -3.9%
1.88
US$48,084 		25,590 -3.9% 1.88 US$48,084
2026-05-21 2026-05-20 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
28,946 -4.4%
1.88
US$54,482 		28,946 -4.4% 1.88 US$54,482
2026-05-20 2026-05-20 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
28,946
1.88
US$54,482 		28,946 1.88 US$54,482
2026-05-20 2026-05-20 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
25,590
1.88
US$48,084 		25,590 1.88 US$48,084
2026-01-12 2026-01-09 S Sale
4.0
TAHL CINDY

See Remarks

Officer
10,589 -2.7%
1.06
US$11,275 		10,589 -2.7% 1.06 US$11,275
2026-01-12 2026-01-09 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
5,190 -1.5%
1.07
US$5,557 		5,190 -1.5% 1.07 US$5,557
2026-01-09 2026-01-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
10,589
1.06
US$11,275 		10,589 1.06 US$11,275
2026-01-09 2026-01-09 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
5,190
1.07
US$5,557 		5,190 1.07 US$5,557
2025-12-29 2025-12-24 PrS Proposed sale
2.6
MENDLEIN JOHN

Former Director

Non-Executive Director
38,428
1.01
US$38,881 		38,428 1.01 US$38,881
2025-08-05 2025-08-04 S Sale
4.0
TAHL CINDY

See Remarks

Officer
9,037 -2.2%
1.06
US$9,573 		9,037 -2.2% 1.06 US$9,573
2025-08-05 2025-08-04 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
14,466 -4.1%
1.06
US$15,396 		14,466 -4.1% 1.06 US$15,396
2025-08-04 2025-08-04 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
9,037
1.06
US$9,573 		9,037 1.06 US$9,573
2025-08-04 2025-08-04 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
14,466
1.06
US$15,396 		14,466 1.06 US$15,396
2025-03-06 2025-03-06 PrS Proposed sale
4.0
Wolchko J Scott

Former Officer and Director

Executive Director
113,178
0.93
US$104,881 		113,178 0.93 US$104,881
2025-01-13 2025-01-10 S Sale
3.3
Bressi Jerome Charles

See Remarks

Officer
5,980 -2.2%
1.55
US$9,269 		5,980 -2.2% 1.55 US$9,269
2025-01-13 2025-01-10 S Sale
4.0
TAHL CINDY

See Remarks

Officer
5,654 -1.7%
1.55
US$8,764 		5,654 -1.7% 1.55 US$8,764
2025-01-13 2025-01-10 S Sale
4.0
Valamehr Bahram

President and CEO

Executive Director
8,705 -2.4%
1.54
US$13,406 		8,705 -2.4% 1.54 US$13,406
2025-01-10 2025-01-10 PrS Proposed sale
4.0
Valamehr Bahram

Officer; Director

Executive Director
8,705
1.54
US$13,447 		8,705 1.54 US$13,447
2025-01-10 2025-01-10 PrS Proposed sale
3.3
Bressi Jerome Charles

Officer

Officer
5,980
1.55
US$9,276 		5,980 1.55 US$9,276
2025-01-10 2025-01-10 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
5,654
1.55
US$8,782 		5,654 1.55 US$8,782
2024-12-26 2024-12-20 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
397,964 +3.2%
1.68
US$668,580 		397,964 +3.2% 1.68 US$668,580
2024-12-26 2024-12-20 S Sale
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
341,633 -2.7%
1.68
US$573,943 		341,633 -2.7% 1.68 US$573,943
2024-12-20 2024-12-20 PrS Proposed sale
3.2
Redmile Group, LLC

Director, 10% Stockholder

Non-Executive Director Large shareholder
341,633
1.66
US$567,111 		341,633 1.66 US$567,111
2024-08-07 2024-08-06 PlS Planned sale
Xu Yuan
Non-Executive Director
633 -6.8%
4.23
US$2,678 		633 -6.8% 4.23 US$2,678
2024-08-06 2024-08-06 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
633
4.23
US$2,678 		633 4.23 US$2,678
2024-03-05 2024-03-04 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
2,447 -2.4%
7.77
US$19,013 		2,447 -2.4% 7.77 US$19,013
2024-03-04 2024-03-04 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
2,447
7.77
US$19,013 		2,447 7.77 US$19,013
2024-01-30 2024-01-29 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
1,849 -1.7%
5.00
US$9,245 		1,849 -1.7% 5.00 US$9,245
2024-01-29 2024-01-29 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
1,849
5.00
US$9,245 		1,849 5.00 US$9,245
2024-01-10 2024-01-09 S Sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
10,874 -7.1%
4.37
US$47,519 		10,874 -7.1% 4.37 US$47,519
2024-01-10 2024-01-09 S Sale
4.0
Valamehr Bahram

Chief R&D Officer

Officer
11,271 -6.7%
4.38
US$49,367 		11,271 -6.7% 4.38 US$49,367
2024-01-10 2024-01-09 S Sale
4.0
Wolchko J Scott

President and CEO

Executive Director
14,391 -3.7%
4.37
US$62,889 		14,391 -3.7% 4.37 US$62,889
2024-01-10 2024-01-09 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
7,028 -6.2%
4.37
US$30,712 		7,028 -6.2% 4.37 US$30,712
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Wolchko J Scott

Officer; Director

Executive Director
14,391
4.37
US$62,958 		14,391 4.37 US$62,958
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
7,028
4.37
US$30,692 		7,028 4.37 US$30,692
2024-01-09 2024-01-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
10,874
4.37
US$47,472 		10,874 4.37 US$47,472
2024-01-09 2024-01-09 PrS Proposed sale
4.0
Valamehr Bahram

Officer

Officer
11,271
4.38
US$49,335 		11,271 4.38 US$49,335
2024-01-03 2024-01-02 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
5,182 -4.4%
3.66
US$18,966 		5,182 -4.4% 3.66 US$18,966
2024-01-02 2024-01-02 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
5,182
3.66
US$18,966 		5,182 3.66 US$18,966
2023-12-28 2023-12-26 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
44,630 +0.3%
3.72
US$166,024 		44,630 +0.3% 3.72 US$166,024
2023-12-19 2023-12-18 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
1,585 -1.3%
3.50
US$5,548 		1,585 -1.3% 3.50 US$5,548
2023-12-18 2023-12-18 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
1,585
3.50
US$5,548 		1,585 3.50 US$5,548
2023-11-13 2023-11-09 PlS Planned sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
24,363 -13.7%
2.40
US$58,471 		24,363 -13.7% 2.40 US$58,471
2023-11-09 2023-11-09 PrS Proposed sale
4.0
TAHL CINDY

Officer

Officer
24,363
2.40
US$58,471 		24,363 2.40 US$58,471
2023-08-21 2023-08-18 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
4,718 -3.8%
2.80
US$13,210 		4,718 -3.8% 2.80 US$13,210
2023-08-18 2023-08-18 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
4,718
2.80
US$13,231 		4,718 2.80 US$13,231
2023-08-07 2023-08-04 PlS Planned sale
Xu Yuan
Non-Executive Director
632 -6.4%
3.71
US$2,345 		632 -6.4% 3.71 US$2,345
2023-08-04 2023-08-04 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
632
3.71
US$2,345 		632 3.71 US$2,345
2023-07-06 2023-07-05 PlS Planned sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
5,182 -4.0%
4.83
US$25,029 		5,182 -4.0% 4.83 US$25,029
2023-07-06 2023-07-05 S Sale
3.2
Powl Brian T.

Chief Commercial Officer

Officer
3,854 -8.6%
4.87
US$18,769 		3,854 -8.6% 4.87 US$18,769
2023-07-05 2023-07-05 PrS Proposed sale
3.2
Powl Brian T.

Officer

Officer
3,854
4.87
US$18,758 		3,854 4.87 US$18,758
2023-07-05 2023-07-05 PrS Proposed sale
4.0
Dulac Edward J III

Officer

Officer
5,182
4.83
US$25,029 		5,182 4.83 US$25,029
2023-06-15 2023-06-14 PlS Planned sale
Xu Yuan
Non-Executive Director
3,460 -25.8%
5.58
US$19,307 		3,460 -25.8% 5.58 US$19,307
2023-06-14 2023-06-14 PrS Proposed sale
Xu Yuan

Director

Non-Executive Director
3,460
5.58
US$19,307 		3,460 5.58 US$19,307
2023-04-21 2023-04-21 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
256,639 +2.0%
6.18
US$1,586,029 		256,639 +2.0% 6.18 US$1,586,029
2023-04-21 2023-04-20 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
20,000 +0.2%
5.99
US$119,800 		20,000 +0.2% 5.99 US$119,800
2023-04-19 2023-04-18 S Sale
4.0
Chu Yu-Waye

Chief Medical Officer

Officer
2,317 -1.6%
6.58
US$15,246 		2,317 -1.6% 6.58 US$15,246
2023-04-19 2023-04-18 S Sale
4.0
Chu Yu-Waye

Chief Medical Officer

Officer
215 -0.2%
6.52
US$1,402 		215 -0.2% 6.52 US$1,402
2023-04-18 2023-04-18 PrS Proposed sale
4.0
Chu Yu-Waye

Officer

Officer
2,532
6.58
US$16,654 		2,532 6.58 US$16,654
2023-04-17 2023-04-14 B Purchase
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
25,700 +0.2%
6.00
US$154,200 		25,700 +0.2% 6.00 US$154,200
2023-04-17 2023-04-14 S Sale
3.2
Redmile Group, LLC
Non-Executive Director Large shareholder
302,339 -2.3%
5.84
US$1,765,660 		302,339 -2.3% 5.84 US$1,765,660
2023-04-14 2023-04-14 PrS Proposed sale
Redmile Capital Offshore Fund (ERISA), Ltd.

Director,10% Stockholder

Non-Executive Director Large shareholder
135,134
5.61
US$758,102 		135,134 5.61 US$758,102
2023-01-13 2023-01-13 B Purchase
2.6
MENDLEIN JOHN
Non-Executive Director
36,631 +14.9%
5.43
US$198,906 		36,631 +14.9% 5.43 US$198,906
2023-01-13 2023-01-11 B Purchase
2.6
MENDLEIN JOHN
Non-Executive Director
88,048 +55.7%
5.67
US$499,232 		88,048 +55.7% 5.67 US$499,232
2023-01-11 2023-01-10 S Sale
4.0
Wolchko J Scott

President and CEO

Executive Director
45,907 -10.6%
5.24
US$240,553 		45,907 -10.6% 5.24 US$240,553
2023-01-11 2023-01-10 S Sale
4.0
Valamehr Bahram

Chief R&D Officer

Officer
10,917 -6.1%
5.24
US$57,205 		10,917 -6.1% 5.24 US$57,205
2023-01-11 2023-01-10 S Sale
4.0
Chu Yu-Waye

Chief Medical Officer

Officer
7,825 -5.2%
5.24
US$41,003 		7,825 -5.2% 5.24 US$41,003
2023-01-11 2023-01-10 S Sale
3.0
Plavsic Mark

Chief Technical Officer

Officer
3,418 -2.7%
5.24
US$17,910 		3,418 -2.7% 5.24 US$17,910
2023-01-11 2023-01-10 S Sale
4.0
TAHL CINDY

General Counsel and Secretary

Officer
11,553 -6.1%
5.24
US$60,538 		11,553 -6.1% 5.24 US$60,538
2023-01-11 2023-01-10 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
7,331 -5.4%
5.24
US$38,414 		7,331 -5.4% 5.24 US$38,414
2022-08-19 2022-08-18 S Sale
4.0
Dulac Edward J III

Chief Financial Officer

Officer
432 -0.3%
30.41
US$13,137 		432 -0.3% 30.41 US$13,137
Explore more

More insider trading research around Fate Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America